Class of 2024
For remarkable contributions to the establishment of immune checkpoint therapies and vaccine technologies, identifying novel alternative checkpoints governing treatment response and resistance, and translating such findings into clinical trials involving immunotherapy combinations designed to improve the standard of care for renal cell carcinoma and bladder cancer patients.
*Full-length biography in development
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]